{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:14:26Z","timestamp":1790889266036,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Doxorubicin (DOX) is an effective antitumor agent, but its clinical usage is limited due to adverse cardiotoxic effects. Several compounds have been studied to reduce DOX cardiotoxicity to improve its therapeutic index. This study was aimed to investigate the protective effects of sodium thiosulfate (STS) pre-treatment against DOX-induced cardiomyopathy in rats.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Male Wistar rats were randomized into 4 groups: control (saline), DOX (2.5\u2009mg\/kg, 3 times per week, intraperitoneal [i.p.]), STS (300\u2009mg\/kg, 3 times per week, i.p), and DOX\u2009+\u2009STS (30\u2009min prior to DOX injection, 3 times per week, i.p.) over a period of 2 weeks. The body weight, electrocardiography, histopathology, papillary muscle contractility, and oxidative stress biomarkers in heart tissues were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The results indicated that STS significantly improved the body weight (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), decreased QRS complex and QT interval on ECG (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05 and <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, respectively), as well as declined the papillary muscle excitation, and increased its contraction (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) compared to DOX-treated rats. STS strongly suppressed oxidative stress induced by DOX through the significant improvement of the cardiac tissue antioxidant capacity by increasing glutathione, superoxide dismutase (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and decreasing the level of lipid peroxidation (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Taken together, the results of this study demonstrated that STS showed potent cardioprotective effects against DOX-induced cardiotoxicity by suppressing oxidative stress.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-022-00569-3","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T09:04:43Z","timestamp":1653469483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cardioprotective effects of sodium thiosulfate against doxorubicin-induced cardiotoxicity in male rats"],"prefix":"10.1186","volume":"23","author":[{"given":"Maryam","family":"Shekari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges Khalilian","family":"Gortany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Khalilzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homanaz","family":"Ghafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Reza","family":"Dehpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ghazi-Khansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"569_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000265166","volume":"115","author":"K Chatterjee","year":"2010","unstructured":"Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology. 2010;115:155\u201362.","journal-title":"Cardiology"},{"key":"569_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","volume":"818","author":"K Renu","year":"2018","unstructured":"Renu K, Abilash V, Pichiah TPB, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy\u2013an update. Eur J Pharmacol. 2018;818:241\u201353.","journal-title":"Eur J Pharmacol"},{"key":"569_CR3","doi-asserted-by":"publisher","first-page":"101394","DOI":"10.1016\/j.redox.2019.101394","volume":"29","author":"B Kalyanaraman","year":"2020","unstructured":"Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree? Redox Biol. 2020;29:101394.","journal-title":"Redox Biol"},{"key":"569_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","volume":"307","author":"M Songbo","year":"2019","unstructured":"Songbo M, Lang H, Xinyong C, Bin X, Ping Z, Liang S. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett. 2019;307:41\u20138.","journal-title":"Toxicol Lett"},{"key":"569_CR5","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639\u201342.","journal-title":"Nat Med"},{"key":"569_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/path.1863","volume":"207","author":"D Lebrecht","year":"2005","unstructured":"Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 2005;207:436\u201344.","journal-title":"J Pathol"},{"key":"569_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00280-019-04019-6","volume":"85","author":"M Sheibani","year":"2020","unstructured":"Sheibani M, Nezamoleslami S, Faghir-Ghanesefat H, Emami AH, Dehpour AR. Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats. Cancer Chemother Pharmacol. 2020;85:563\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"key":"569_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4037\/ccn2011799","volume":"31","author":"J Hamel","year":"2011","unstructured":"Hamel J. A review of acute cyanide poisoning with a treatment update. Crit Care Nurse. 2011;31:72\u201381 quiz 82.","journal-title":"Crit Care Nurse"},{"key":"569_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000380945","volume":"5","author":"Z Yu","year":"2015","unstructured":"Yu Z, Gu L, Pang H, Fang Y, Yan H, Fang W. Sodium thiosulfate: an emerging treatment for calciphylaxis in dialysis patients. Case Rep Nephrol Dial. 2015;5:77\u201382.","journal-title":"Case Rep Nephrol Dial"},{"key":"569_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2165\/11316640-000000000-00000","volume":"32","author":"RY Tsang","year":"2009","unstructured":"Tsang RY, Al-Fayea T, Au HJ. Cisplatin overdose: toxicities and management. Drug Saf. 2009;32:1109\u201322.","journal-title":"Drug Saf"},{"key":"569_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-4-1","volume":"4","author":"MR Hayden","year":"2005","unstructured":"Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R. Vascular ossification\u2013calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis\u2013calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol. 2005;4:1\u201322.","journal-title":"Cardiovasc Diabetol"},{"key":"569_CR12","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1097\/ALN.0000000000000456","volume":"121","author":"M Sakaguchi","year":"2014","unstructured":"Sakaguchi M, Marutani E, Shin HS, Chen W, Hanaoka K, Xian M, et al. Sodium thiosulfate attenuates acute lung injury in mice. Anesthesiology. 2014;121:1248\u201357.","journal-title":"Anesthesiology"},{"key":"569_CR13","doi-asserted-by":"publisher","first-page":"650968","DOI":"10.3389\/fphar.2021.650968","volume":"12","author":"ITN Nguyen","year":"2021","unstructured":"Nguyen ITN, Wiggenhauser LM, Bulthuis M, Hillebrands JL, Feelisch M, Verhaar MC, et al. Cardiac protection by Oral sodium thiosulfate in a rat model of L-NNA-induced heart disease. Front Pharmacol. 2021;12:650968.","journal-title":"Front Pharmacol"},{"key":"569_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12013-019-00871-8","volume":"77","author":"S Kannan","year":"2019","unstructured":"Kannan S, Boovarahan SR, Rengaraju J, Prem P, Kurian GA. Attenuation of cardiac ischemia-reperfusion injury by sodium thiosulfate is partially dependent on the effect of cystathione beta synthase in the myocardium. Cell Biochem Biophys. 2019;77:261\u201372.","journal-title":"Cell Biochem Biophys"},{"key":"569_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10557-017-6751-0","volume":"31","author":"S Ravindran","year":"2017","unstructured":"Ravindran S, Boovarahan SR, Shanmugam K, Vedarathinam RC, Kurian GA. Sodium thiosulfate preconditioning ameliorates ischemia\/reperfusion injury in rat hearts via reduction of oxidative stress and apoptosis. Cardiovasc Drugs Ther. 2017;31:511\u201324.","journal-title":"Cardiovasc Drugs Ther"},{"key":"569_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4172\/pharmaceutical-sciences.1000163","volume":"78","author":"AS Banu","year":"2016","unstructured":"Banu AS, Shifana AN, Fathima MN, Kurian GA. Effect of sodium thiosulfate on isolated cardiac Interfibrillar and Subsarcolemmal mitochondria. Indian J Pharm Sci. 2016;78:641\u201350.","journal-title":"Indian J Pharm Sci"},{"key":"569_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000156486","volume":"82","author":"U Sen","year":"2008","unstructured":"Sen U, Vacek TP, Hughes WM, Kumar M, Moshal KS, Tyagi N, et al. Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. Pharmacology. 2008;82:201\u201313.","journal-title":"Pharmacology"},{"key":"569_CR18","doi-asserted-by":"publisher","first-page":"118074","DOI":"10.1016\/j.lfs.2020.118074","volume":"257","author":"Y Mizuta","year":"2020","unstructured":"Mizuta Y, Tokuda K, Guo J, Zhang S, Narahara S, Kawano T, et al. Sodium thiosulfate prevents doxorubicin-induced DNA damage and apoptosis in cardiomyocytes in mice. Life Sci. 2020;257:118074.","journal-title":"Life Sci"},{"key":"569_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cbi.2015.12.010","volume":"244","author":"R Wu","year":"2016","unstructured":"Wu R, Wang HL, Yu HL, Cui XH, Xu MT, Xu X, et al. Doxorubicin toxicity changes myocardial energy metabolism in rats. Chem Biol Interact. 2016;244:149\u201358.","journal-title":"Chem Biol Interact"},{"key":"569_CR20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.lfs.2018.06.022","volume":"207","author":"M Khalilzadeh","year":"2018","unstructured":"Khalilzadeh M, Abdollahi A, Abdolahi F, Abdolghaffari AH, Dehpour AR, Jazaeri F. Protective effects of magnesium sulfate against doxorubicin induced cardiotoxicity in rats. Life Sci. 2018;207:436\u201341.","journal-title":"Life Sci"},{"key":"569_CR21","first-page":"865","volume":"62","author":"ME Billingham","year":"1978","unstructured":"Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62:865\u201372.","journal-title":"Cancer Treat Rep"},{"key":"569_CR22","doi-asserted-by":"publisher","first-page":"670479","DOI":"10.3389\/fphar.2021.670479","volume":"12","author":"EY Podyacheva","year":"2021","unstructured":"Podyacheva EY, Kushnareva EA, Karpov AA, Toropova YG. Analysis of models of doxorubicin-induced cardiomyopathy in rats and mice. A modern view from the perspective of the Pathophysiologist and the clinician. Front Pharmacol. 2021;12:670479.","journal-title":"Front Pharmacol"},{"key":"569_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/cvr\/cvn192","volume":"80","author":"TJ Liu","year":"2008","unstructured":"Liu TJ, Yeh YC, Ting CT, Lee WL, Wang LC, Lee HW, et al. Ginkgo biloba extract 761 reduces doxorubicin-induced apoptotic damage in rat hearts and neonatal cardiomyocytes. Cardiovasc Res. 2008;80:227\u201335.","journal-title":"Cardiovasc Res"},{"key":"569_CR24","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1111\/bph.13791","volume":"174","author":"D Cappetta","year":"2017","unstructured":"Cappetta D, Esposito G, Coppini R, Piegari E, Russo R, Ciuffreda LP, et al. Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction. Br J Pharmacol. 2017;174:3696\u2013712.","journal-title":"Br J Pharmacol"},{"key":"569_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacme.2015.02.003","volume":"5","author":"VS Warpe","year":"2015","unstructured":"Warpe VS, Mali VR, Arulmozhi S, Bodhankar SL, Mahadik KR. Cardioprotective effect of ellagic acid on doxorubicin induced cardiotoxicity in wistar rats. J Acute Med. 2015;5:1\u20138.","journal-title":"J Acute Med"},{"key":"569_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s002800050048","volume":"45","author":"EH Herman","year":"2000","unstructured":"Herman EH, Zhang J, Chadwick DP, Ferrans VJ. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol. 2000;45:329\u201334.","journal-title":"Cancer Chemother Pharmacol"},{"key":"569_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tox.2007.09.026","volume":"243","author":"RB Kelishomi","year":"2008","unstructured":"Kelishomi RB, Ejtemaeemehr S, Tavangar SM, Rahimian R, Mobarakeh JI, Dehpour AR. Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology. 2008;243:96\u2013104.","journal-title":"Toxicology"},{"key":"569_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejphar.2016.12.022","volume":"796","author":"F Yarmohmmadi","year":"2017","unstructured":"Yarmohmmadi F, Rahimi N, Faghir-Ghanesefat H, Javadian N, Abdollahi A, Pasalar P, et al. Protective effects of agmatine on doxorubicin-induced chronic cardiotoxicity in rat. Eur J Pharmacol. 2017;796:39\u201344.","journal-title":"Eur J Pharmacol"},{"key":"569_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1046\/j.1365-2796.1999.00480.x","volume":"245","author":"T Nousiainen","year":"1999","unstructured":"Nousiainen T, Vanninen E, Rantala A, Jantunen E, Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin\u2019s lymphoma. J Intern Med. 1999;245:359\u201364.","journal-title":"J Intern Med"},{"key":"569_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-0773.1994.tb00330.x","volume":"75","author":"F Rossi","year":"1994","unstructured":"Rossi F, Filippelli W, Russo S, Filippelli A, Berrino L. Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacol Toxicol. 1994;75:99\u2013107.","journal-title":"Pharmacol Toxicol"},{"key":"569_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s002800050453","volume":"38","author":"SA van Acker","year":"1996","unstructured":"van Acker SA, Kramer K, Voest EE, Grimbergen JA, Zhang J, van der Vijgh WJ, et al. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. Cancer Chemother Pharmacol. 1996;38:95\u2013101.","journal-title":"Cancer Chemother Pharmacol"},{"key":"569_CR32","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1006\/jmcc.1997.0494","volume":"29","author":"RJ Boucek Jr","year":"1997","unstructured":"Boucek RJ Jr, Dodd DA, Atkinson JB, Oquist N, Olson RD. Contractile failure in chronic doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol. 1997;29:2631\u201340.","journal-title":"J Mol Cell Cardiol"},{"key":"569_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/cells7100144","volume":"7","author":"RB Subbarao","year":"2018","unstructured":"Subbarao RB, Ok SH, Lee SH, Kang D, Kim EJ, Kim JY, et al. Lipid emulsion inhibits the late apoptosis\/cardiotoxicity induced by doxorubicin in rat Cardiomyoblasts. Cells. 2018;7:144.","journal-title":"Cells"},{"key":"569_CR34","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s13105-014-0339-y","volume":"70","author":"MH Arafa","year":"2014","unstructured":"Arafa MH, Mohammad NS, Atteia HH, Abd-Elaziz HR. Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem. 2014;70:701\u201311.","journal-title":"J Physiol Biochem"},{"key":"569_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.phymed.2018.01.009","volume":"40","author":"J Yu","year":"2018","unstructured":"Yu J, Wang C, Kong Q, Wu X, Lu JJ, Chen X. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Phytomedicine. 2018;40:125\u201339.","journal-title":"Phytomedicine"},{"key":"569_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cbi.2017.07.002","volume":"274","author":"S Ravindran","year":"2017","unstructured":"Ravindran S, Jahir Hussain S, Boovarahan SR, Kurian GA. Sodium thiosulfate post-conditioning protects rat hearts against ischemia reperfusion injury via reduction of apoptosis and oxidative stress. Chem Biol Interact. 2017;274:24\u201334.","journal-title":"Chem Biol Interact"},{"key":"569_CR37","doi-asserted-by":"publisher","first-page":"795602","DOI":"10.1155\/2015\/795602","volume":"2015","author":"P Angsutararux","year":"2015","unstructured":"Angsutararux P, Luanpitpong S, Issaragrisil S. Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress. Oxidative Med Cell Longev. 2015;2015:795602.","journal-title":"Oxidative Med Cell Longev"},{"key":"569_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/MPH.0000000000001118","volume":"40","author":"K Liesse","year":"2018","unstructured":"Liesse K, Harris J, Chan M, Schmidt ML, Chiu B. Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumor patients-a systematic review. J Pediatr Hematol Oncol. 2018;40:417.","journal-title":"J Pediatr Hematol Oncol"},{"key":"569_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-019-0036-7","volume":"5","author":"S Ganatra","year":"2019","unstructured":"Ganatra S, Nohria A, Shah S, Groarke JD, Sharma A, Venesy D, et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-oncology. 2019;5:1\u201312.","journal-title":"Cardio-oncology"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00569-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-022-00569-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00569-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T09:05:47Z","timestamp":1653469547000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-022-00569-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1186\/s40360-022-00569-3","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed with the relevant guidelines and regulations and compliance with ARRIVE guidelines for the care and use of experimental animals by the committee for supervision of Experiment on animals (CPCSEA) and the National Institute of Health NIH Protocol. Ethical approval was obtained from the Research and Ethics Committee of Tehran University of Medical Sciences for care and use of laboratory animals (approval number IR.TUMS.MEDICINE.REC.1397.178).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}